Enhanced infiltration of activated cytotoxic (GrB+ CD8+ T cells) tumor-infiltrating T cells has been reported in mice treated with the combination regimen (Figure 5, p ≤ 0.01, combination therapy vs. control). The gene discussed is CD8A; the disease is neoplasm.